Join our community of smart investors

Chi-Med bolsters commercial team

The bio-pharma group has eight drug candidates in play
March 4, 2020

Full-year numbers for Hutchison China Meditech (HCM) remain of secondary importance to clinical development. The bio-pharma group closed out 2019 with $17.6m (£13.5m) in sales linked to its Elunate (colorectal cancer) product, with the prospect of multiple global registration studies this year, and the further development of eight clinical drug candidates, five of which are globally focused. Clinical development comes at a cost, with eventual returns uncertain or long-dated. So, the net loss from the innovation platform attributable to Chi-Med was up by over a quarter year on year to $133m.

IC TIP: Buy at 380p
This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in